An Anti-PD-1 Antibody

DRUG2 trials

Sponsors

LaNova Australia Pty Limited, LaNova Medicines Limited

Conditions

Advanced Solid Tumor

Phase 1

Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

CompletedNCT05199753

LaNova Australia Pty LimitedAdvanced Solid Tumor

Start: 2022-03-16End: 2024-12-31Updated: 2025-09-12

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

TerminatedNCT05255484

LaNova Medicines LimitedAdvanced Solid Tumor

Start: 2022-05-26End: 2023-10-06Updated: 2023-10-25

Related Papers

Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies.

Journal of Clinical Oncology2025-05-282 citations

Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies.

Journal of Clinical Oncology2024-06-016 citations

139P Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors: Results of phase I study

Immuno-Oncology Technology2023-12-011 citations